Edwards raises its 2026 outlook a third time on $1.24B of TAVR sales

MedDevice Startups Staff · 2 days ago · 2 min read · Via MedTech Dive

Edwards Lifesciences reported $1.72B of third quarter sales, up 10.5 percent. TAVR brought in $1.24B, up 8 percent. Transcatheter mitral and tricuspid therapies reached $207M on an adjusted basis, up 44 percent.

The company raised its 2026 constant currency growth forecast to about 11.5 percent, from a range of 10 to 11 percent. That is the third raise this year. The TMTT outlook moved to $780M to $790M, from $760M to $780M.

At TCT 2026 Edwards presented PROGRESS, which showed Sapien 3 superior to clinical surveillance in patients with moderate aortic stenosis and at-risk features. CMS issued a final national coverage determination during the quarter extending coverage to asymptomatic severe aortic stenosis. That follows the April 2025 label expansion built on EARLY TAVR.

The TMTT line matters more than the TAVR line for structural heart startups. A 44 percent growth rate on a $207M quarterly base marks a market still being built, which is where incumbents tend to pay for a pipeline rather than a predicate.

Questions & Answers

What were Edwards Lifesciences' third quarter 2026 results?

Edwards Lifesciences reported $1.72 billion in third quarter 2026 sales, up 10.5 percent year over year. TAVR sales were $1.24 billion, up 8 percent, and adjusted transcatheter mitral and tricuspid therapies sales were $207 million, up 44 percent.

What is Edwards Lifesciences' 2026 sales guidance?

Edwards raised its 2026 constant currency sales growth forecast to about 11.5 percent, up from a prior range of 10 to 11 percent. It was the third raise of the year, and the company lifted its TMTT outlook to $780 million to $790 million.

What did the Edwards PROGRESS trial show?

PROGRESS, presented at TCT 2026, showed the Edwards Sapien 3 TAVR device was superior to clinical surveillance in patients with moderate aortic stenosis who had at-risk features.

← Back to Startups